Rti Biologics (RTIX) 4.52 $RTIX
Sirona Dental Q2 Earnings and Revs Beat Ests; Shares up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 12, 11:10AM CDT
Sirona Dental Systems, Inc. (SIRO) anticipates adjusted earnings in the range of $3.60 to $3.70 per share for fiscal 2014, implying a growth of 6-9%.
ArthroCare Q1 Earnings Miss Ests; Revs In Line - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 09, 8:30AM CDT
ArthroCare Corp.'s (ARTC) total revenues for the quarter stood at $96.1 million, reflecting an increase of 4.0% from $92.3 million in the first quarter of 2013.
Mindray Medical International Limited (MR) Crumbles: Stock Falls by 6.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed May 07, 7:50AM CDT
Mindray has seen negative earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month
Volcano Slips into Loss, Misses Ests in Q1 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 06, 11:10AM CDT
Following the earnings announcement Volcano's share price dropped 0.2% to $17.5 on May 5.
Why RTI Surgical (RTIX) Could Be Positioned for a Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue May 06, 7:49AM CDT
RTI Surgical may be an interesting play for investors, as it is seeing solid activity on the earnings estimate revision front
Accuray Posts Narrower-than-Expected Q3 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 05, 9:20AM CDT
Accuray Incorporated (ARAY) raised its total revenue guidance for fiscal 2014 to a range of $355 to $365 million from the previous range of $340 to $350 million.
RTI Biologics Up 5.7%, Shares Break Through Resistance (RTIX)
Comtex SmarTrend(R) - Fri May 02, 11:40AM CDT
RTI Biologics (NASDAQ:RTIX) is one of today's best performing low-priced stocks, up 5.7% to $4.65 on 1.4x average daily volume. RTI Biologics has traded 320,000 shares thus far today, vs. average volume of 237,000 shares per day. The stock has outperformed the Dow (5.7% to the Dow's -0.1%) and outperformed the S&P 500 (5.7% to the S&P's 0.0%) during today's trading.
Can the Rally in RTI Surgical (RTIX) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu May 01, 6:12AM CDT
Can the Rally in RTI Surgical (RTIX) Shares Continue?
What Makes Intuitive Surgical (ISRG) a Strong Sell? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 7:59AM CDT
Intuitive Surgical (ISRG) has witnessed a significant price decline in the past four weeks and it has seen negative earnings estimate revisions for the current quarter and the current year. It could be time to get rid of the security before more losses hit your portfolio.
Upgrade Alert for RTI Biologics (RTIX)
Comtex SmarTrend(R) - Fri Apr 25, 6:58AM CDT
RTI Biologics (NASDAQ:RTIX) was upgraded from Hold to Buy at Canaccord Genuity today. The stock closed yesterday at $3.93 on volume of 146,000 shares, below average daily volume of 229,000. RTI Biologics share prices have moved between a 52-week high of $5.11 and a 52-week low of $2.54 and closed yesterday at 55% above that low price at $3.93 per share. The 200-day and 50-day moving averages have moved 0.03% lower and 1.43% higher over the past week, respectively.
RTI Surgical(TM) Announces 2014 First Quarter Results
Business Wire - Thu Apr 24, 7:01AM CDT
--Raises revenue guidance for full year 2014
RTI Surgical(TM) Announces Launch of Streamline(R) OCT System
Business Wire - Mon Apr 21, 8:00AM CDT
RTI Surgical Inc. (RTI) (Nasdaq: RTIX), a leading global surgical implant company, announced today the full market launch of the Streamline(R) OCT System. The system is designed to promote fusion of the occipto-cervico-thoracic spine (or occiput-T3). RTI received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the system in March 2014.
RTI Surgical(R) Schedules 2014 First Quarter Earnings Conference Call for April 24, 2014
Business Wire - Thu Apr 17, 8:00AM CDT
RTI Surgical Inc. (RTI) (Nasdaq: RTIX), a global surgical implant company, announced today that it plans to release financial results from the first quarter 2014 on Thursday, April 24, 2014, prior to the market open.
Orthobiologics Market Report 2013-2019: Allografts, Viscosupplements, DBM, BMP, Stem Cell and Others
M2 - Tue Mar 18, 11:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z3l28c/orthobiologics) has announced the addition of the "Orthobiologics Market Report 2013-2019: Allografts, Viscosupplements, DBM, BMP, Stem Cell and Others" report to their offering. The global orthobiologics market was valued at USD 3,754.6 million in 2012 and is expected to grow at a CAGR of 5.9% from 2013 to 2019 to reach at an estimated value of USD 5,519.9 million in 2019. This research report on orthobiologics provides detailed analysis of the global market and helps in understanding the driving forces responsible for the growth of this market. The report discusses the market of orthobiologics on the basis of different orthobiologic products and applications. The product segment comprises allografts, demineralized bone matrix (DBM), bone morphogenetic proteins (BMPs), viscosupplementation, synthetic bone graft substitutes, stem cell based products and machined bone. The application segment is classified into spinal fusion, trauma and reconstructive surgeries. Orthobiology is a branch of science that develops bone and tissue replacement materials for skeletal and tissue healing. Orthobiologics has been gaining popularity since it provides accelerated healing, faster recovery and reduction in number of hospital visits. A rise in the incidence of arthritis and geriatric population has triggered the growth of this market. Moreover, an increase in the obesity rate coupled with rise in demand for minimally invasive procedures has created a considerable demand for bone graft substitutes. In addition, technological advancements, growing patient awareness, rising incidences of road accidents and rising participation in sports related activities has considerably augmented the growth of this market. Market size estimates and forecasts for the period 2011 to 2019 have been provided for each of the segments, in terms of USD million, using 2012 as the base year. The CAGR (%) of each market segment for the forecast period 2013 to 2019 has been provided along with market size estimations. Scope of the Report Products - Allografts - Machined Bones - Demineralized Bone Matrix (DBM) - Bone Morphogenetic Proteins (BMPs) - Viscosupplementation - Stem Cell Therapy - Synthetic Bone Substitutes Applications - Spinal Fusion - Trauma - Reconstructive Surgery Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Orthobiologics Market, by Product Chapter 5 Global Orthobiologics Market, by Application Chapter 6 Global Orthobiologics Market, by Geography Chapter 7 Global Orthobiologics Market Share Analysis Chapter 8 Recommendations Chapter 9 Company Profiles - Alphatec Spine, Inc. - Bacterin International, Inc. - Biomet, Inc. - DePuy Synthes, Inc. (A Johnson & Johnson Company) - Exactech, Inc. - Globus Medical, Inc. - Integra LifeSciences Corporation - Medtronic, Inc. - NuVasive, Inc. - Orthofix Holdings, Inc. - Regeneration Technologies, Inc. - Sanofi - Stryker Corporation - Wright Medical Technology, Inc. - Zimmer Holdings, Inc. For more information visit http://www.researchandmarkets.com/research/z3...obiologics
2014 Bone Grafts Global Strategic Business Report - Growing Clinical Use of Bone Graft Substitutes in Surgical Procedures
M2 - Thu Mar 13, 4:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dtgc4c/bone_grafts) has announced the addition of the "Bone Grafts - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Bone Grafts in US$ Million. The US market for Bone Graft Substitutes is also analyzed by the following segments: Standard Allografts, Machined Bone Allografts, Demineralized Bone Matrix (DBM), Bone Morphogenetic Protein (BMP), Stem Cell Based Bone Grafts, and Synthetic Bone Grafts. The report provides separate comprehensive analytics for the US, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2012 through 2020. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Key Topics Covered I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. INDUSTRY OVERVIEW 2. MARKET DYNAMICS 3. PRODUCT OVERVIEW 4. REGULATORY ENVIRONMENT & REIMBURSEMENTS 5. PRODUCT INNOVATIONS/INTRODUCTIONS - AlloSource Introduces AlloMend - Orthofix Launches Trinity? ELITE - Synergy Biomedical to Introduce Biosphere Putty - K2M Launches VENADO Bone Graft Systems - Bonesupport Receives CE Mark Approval for Cerament|G resorbable - PlusLife? Launches Innovative Allogeneic Bone Gel for Orthopedic Uses (Australia) - RTI Surgical Introduces BioReady DBM Putty - K2M Rolls Out VESUVIUS Osteobiologic Systems - BioHorizons Introduces MinerOss? Cancellous - Amedica Introduces Dynamic Bone - Orthogen Introduces NanoGen - SIRAKOSS Introduces MaxSi - BioMimetic to Introduce Augmatrix Biocomposite Bone Graft Line - Orthofix International Introduces Collage Osteoconductive Scaffold - BioMimetic Obtains Approval from TGA for Commercialization of Augment? Bone Graft - Medtronic Launches ARTISAN Space Maintenance System - NovaBone Introduces MacroPor-Si - RTI Surgical Announces First Application of map3TM Cellular Allogeneic Bone Graft in Ankle and Foot Fusion Procedures ( US) - Integra Receives FDA Clearance for Accell Evo3 - RTI Surgical Introduces BioAdapt DBM Foam - Integra Unveils Trel-Xpress Demineralized Bone Matrix - Keystone Dental Introduces DynaMatrix Plus - Wright Introduces FUSIONFLEX Demineralized Moldable Scaffold - Micromedics Launches OsteoXpress 15cc Bone Graft Delivery Device - Bacterin Unveils OsteoSponge?SC - Integra Launches Allograft Cancellous Sponge - Orthos Receives CE Approval for ?Gel Synthetic Bone Graft Substitute 6. RECENT INDUSTRY ACTIVITY - RTI Biologics Acquires Pioneer Surgical Technology - Wright Medical Group Acquires BioMimetic Therapeutics - Titan Spine Enters into Distribution Agreement with Biomet - Bioventus and Pfizer Enter into Agreement - AlloSource Enters into Partnership with Humacyte - MicroPort Medical to Acquire OrthoRecon Business of Wright Medical Group - J&J Takes Over Synthes - Stryker Acquires Orthovita - Zimmer Dental and Curasan Enter into Distribution Agreement - Cayenne Medical Enters into Partnership with Parametrics Medical - NuVasive Signs Licensing Agreement with AlloSource - Stryker Divests OP-1 Product Range 7. FOCUS ON SELECT PLAYERS 8. MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. EUROPE 3. REST OF WORLD IV. COMPETITIVE LANDSCAPE Companies Mentioned The report profiles 61 companies including many key and niche players such as: - AlloSource - Biomet - DePuy Synthes - Synthes - DePuy Spine - Exactech - Integra LifeSciences - LifeNet Health - Medtronic - NovaBone Products - NuVasive, - Olympus Biotech - RTI Surgical - Smith & Nephew - Stryker - Wright Medical Technology - BioMimetic Therapeutics - Zimmer For more information visit http://www.researchandmarkets.com/research/dt...one_grafts About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Why RTI Surgical, Inc. Shares Temporarily Spiked Higher
Sean Williams, The Motley Fool - Motley Fool - Wed Mar 12, 12:54PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of RTI Surgical , a producer of orthopedic...
Traders Get Bullish on Shares of RTI Biologics, Shares Up 7.1% (RTIX)
Comtex SmarTrend(R) - Wed Mar 12, 10:12AM CDT
RTI Biologics (NASDAQ:RTIX) is one of today's best performing low-priced stocks, up 7.1% to $4.23 on 1.6x average daily volume. Thus far today, RTI Biologics has traded 409,000 shares, vs. average volume of 262,000 shares per day. The stock has outperformed the Dow (7.1% to the Dow's -0.2%) and outperformed the S&P 500 (7.1% to the S&P's -0.2%) during today's trading.
RTI Surgical(TM) Launches Two Natural Bone Grafting Solutions at AAOS Annual Meeting
Business Wire - Wed Mar 12, 7:00AM CDT
RTI Surgical Inc. (RTI) (Nasdaq: RTIX), a leading global surgical implant company, is launching two new biological solutions at the American Academy of Orthopaedic Surgeons (AAOS) annual meeting in New Orleans this week. NanOss(R) Bioactive 3D, a synthetic three dimensional bioscaffold which supports bone formation, and map3(TM) Cellular Allogeneic Bone Graft, an implant that contains the three essential elements needed to generate and maintain new bone, will be introduced at the RTI Surgical exhibit at booth 5937 (Hall H) during the AAOS meeting.
Concise Analysis of the United States Regenerative Medicine Market - Forecasts to 2016
M2 - Wed Mar 12, 6:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4lq46f/regenerative) has announced the addition of the "Concise Analysis of the United States Regenerative Medicine Market - Forecasts to 2016" report to their offering. There is a high demand for synthetic organ transplants in the market. Regenerative medicine helps in the development of artificial organs. The introduction of artificial organs for implantation is expected to encourage many vendors and research organizations to develop advanced stem cell products, therapies, and regenerative products. It will also help reduce the long organ waiting list. For instance, custom-made windpipe can be made using regenerative products within a week. The first ever implant of a synthetic trachea took place in June 2011. The synthetic trachea was made from minuscule plastic fibers and was covered in stem cells taken from a human bone marrow. Surgeons successfully implanted this synthetic trachea into a 36-year-old patient with late-stage tracheal cancer at Karolinska University Hospital in Stockholm. Thus, the use of synthetic organs in transplant surgeries is expected to have a positive impact on the growth of the market. According to the report, one of the main drivers of this market is the increasing prevalence of degenerative diseases. Regenerative products have helped in addressing the unmet needs of various disease areas. Another major driver of the market is the significant advances seen in R&D. Key Topics Covered: 1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 5. Scope of the Report 6. Market Landscape 7. Vendor Landscape 8. Buying Criteria 9. Market Growth Drivers 10. Drivers and their Impact 11. Market Challenges 12. Impact of Drivers and Challenges 13. Market Trends 14. Key Vendor Analysis 15. Other Reports in this Series Companies Mentioned: - Advanced Cell Technology Inc. - Arteriocyte Inc. - Athersys Inc. - Baxter International Inc. - CryoLife - Cytori Therapeutics Inc. - Genzyme Corp. - Geron Corp. - InVivo Therapeutics - Inc. - Integra Life Sciences Holdings Corp. - Kensey Nash Corp. - Kinetic Concepts Inc. - Medtronic Inc. - NeoStem Inc. - Osiris Therapeutics Inc. - Osteotech Inc. - RTI Biologics Inc. - Stryker Corp. - Zimmer Holdings Inc. For more information visit http://www.researchandmarkets.com/research/4l...generative
Sirona Dental Q2 Earnings and Revs Beat Ests; Shares up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 12, 11:10AM CDT
Sirona Dental Systems, Inc. (SIRO) anticipates adjusted earnings in the range of $3.60 to $3.70 per share for fiscal 2014, implying a growth of 6-9%.
ArthroCare Q1 Earnings Miss Ests; Revs In Line - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 09, 8:30AM CDT
ArthroCare Corp.'s (ARTC) total revenues for the quarter stood at $96.1 million, reflecting an increase of 4.0% from $92.3 million in the first quarter of 2013.
Mindray Medical International Limited (MR) Crumbles: Stock Falls by 6.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed May 07, 7:50AM CDT
Mindray has seen negative earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month
Volcano Slips into Loss, Misses Ests in Q1 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 06, 11:10AM CDT
Following the earnings announcement Volcano's share price dropped 0.2% to $17.5 on May 5.
Why RTI Surgical (RTIX) Could Be Positioned for a Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue May 06, 7:49AM CDT
RTI Surgical may be an interesting play for investors, as it is seeing solid activity on the earnings estimate revision front
Accuray Posts Narrower-than-Expected Q3 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 05, 9:20AM CDT
Accuray Incorporated (ARAY) raised its total revenue guidance for fiscal 2014 to a range of $355 to $365 million from the previous range of $340 to $350 million.
RTI Biologics Up 5.7%, Shares Break Through Resistance (RTIX)
Comtex SmarTrend(R) - Fri May 02, 11:40AM CDT
RTI Biologics (NASDAQ:RTIX) is one of today's best performing low-priced stocks, up 5.7% to $4.65 on 1.4x average daily volume. RTI Biologics has traded 320,000 shares thus far today, vs. average volume of 237,000 shares per day. The stock has outperformed the Dow (5.7% to the Dow's -0.1%) and outperformed the S&P 500 (5.7% to the S&P's 0.0%) during today's trading.
Can the Rally in RTI Surgical (RTIX) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu May 01, 6:12AM CDT
Can the Rally in RTI Surgical (RTIX) Shares Continue?
What Makes Intuitive Surgical (ISRG) a Strong Sell? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 7:59AM CDT
Intuitive Surgical (ISRG) has witnessed a significant price decline in the past four weeks and it has seen negative earnings estimate revisions for the current quarter and the current year. It could be time to get rid of the security before more losses hit your portfolio.
Upgrade Alert for RTI Biologics (RTIX)
Comtex SmarTrend(R) - Fri Apr 25, 6:58AM CDT
RTI Biologics (NASDAQ:RTIX) was upgraded from Hold to Buy at Canaccord Genuity today. The stock closed yesterday at $3.93 on volume of 146,000 shares, below average daily volume of 229,000. RTI Biologics share prices have moved between a 52-week high of $5.11 and a 52-week low of $2.54 and closed yesterday at 55% above that low price at $3.93 per share. The 200-day and 50-day moving averages have moved 0.03% lower and 1.43% higher over the past week, respectively.
RTI Surgical(TM) Announces 2014 First Quarter Results
Business Wire - Thu Apr 24, 7:01AM CDT
--Raises revenue guidance for full year 2014
RTI Surgical(TM) Announces Launch of Streamline(R) OCT System
Business Wire - Mon Apr 21, 8:00AM CDT
RTI Surgical Inc. (RTI) (Nasdaq: RTIX), a leading global surgical implant company, announced today the full market launch of the Streamline(R) OCT System. The system is designed to promote fusion of the occipto-cervico-thoracic spine (or occiput-T3). RTI received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the system in March 2014.
RTI Surgical(R) Schedules 2014 First Quarter Earnings Conference Call for April 24, 2014
Business Wire - Thu Apr 17, 8:00AM CDT
RTI Surgical Inc. (RTI) (Nasdaq: RTIX), a global surgical implant company, announced today that it plans to release financial results from the first quarter 2014 on Thursday, April 24, 2014, prior to the market open.
Orthobiologics Market Report 2013-2019: Allografts, Viscosupplements, DBM, BMP, Stem Cell and Others
M2 - Tue Mar 18, 11:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z3l28c/orthobiologics) has announced the addition of the "Orthobiologics Market Report 2013-2019: Allografts, Viscosupplements, DBM, BMP, Stem Cell and Others" report to their offering. The global orthobiologics market was valued at USD 3,754.6 million in 2012 and is expected to grow at a CAGR of 5.9% from 2013 to 2019 to reach at an estimated value of USD 5,519.9 million in 2019. This research report on orthobiologics provides detailed analysis of the global market and helps in understanding the driving forces responsible for the growth of this market. The report discusses the market of orthobiologics on the basis of different orthobiologic products and applications. The product segment comprises allografts, demineralized bone matrix (DBM), bone morphogenetic proteins (BMPs), viscosupplementation, synthetic bone graft substitutes, stem cell based products and machined bone. The application segment is classified into spinal fusion, trauma and reconstructive surgeries. Orthobiology is a branch of science that develops bone and tissue replacement materials for skeletal and tissue healing. Orthobiologics has been gaining popularity since it provides accelerated healing, faster recovery and reduction in number of hospital visits. A rise in the incidence of arthritis and geriatric population has triggered the growth of this market. Moreover, an increase in the obesity rate coupled with rise in demand for minimally invasive procedures has created a considerable demand for bone graft substitutes. In addition, technological advancements, growing patient awareness, rising incidences of road accidents and rising participation in sports related activities has considerably augmented the growth of this market. Market size estimates and forecasts for the period 2011 to 2019 have been provided for each of the segments, in terms of USD million, using 2012 as the base year. The CAGR (%) of each market segment for the forecast period 2013 to 2019 has been provided along with market size estimations. Scope of the Report Products - Allografts - Machined Bones - Demineralized Bone Matrix (DBM) - Bone Morphogenetic Proteins (BMPs) - Viscosupplementation - Stem Cell Therapy - Synthetic Bone Substitutes Applications - Spinal Fusion - Trauma - Reconstructive Surgery Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Orthobiologics Market, by Product Chapter 5 Global Orthobiologics Market, by Application Chapter 6 Global Orthobiologics Market, by Geography Chapter 7 Global Orthobiologics Market Share Analysis Chapter 8 Recommendations Chapter 9 Company Profiles - Alphatec Spine, Inc. - Bacterin International, Inc. - Biomet, Inc. - DePuy Synthes, Inc. (A Johnson & Johnson Company) - Exactech, Inc. - Globus Medical, Inc. - Integra LifeSciences Corporation - Medtronic, Inc. - NuVasive, Inc. - Orthofix Holdings, Inc. - Regeneration Technologies, Inc. - Sanofi - Stryker Corporation - Wright Medical Technology, Inc. - Zimmer Holdings, Inc. For more information visit http://www.researchandmarkets.com/research/z3...obiologics
2014 Bone Grafts Global Strategic Business Report - Growing Clinical Use of Bone Graft Substitutes in Surgical Procedures
M2 - Thu Mar 13, 4:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dtgc4c/bone_grafts) has announced the addition of the "Bone Grafts - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Bone Grafts in US$ Million. The US market for Bone Graft Substitutes is also analyzed by the following segments: Standard Allografts, Machined Bone Allografts, Demineralized Bone Matrix (DBM), Bone Morphogenetic Protein (BMP), Stem Cell Based Bone Grafts, and Synthetic Bone Grafts. The report provides separate comprehensive analytics for the US, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2012 through 2020. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Key Topics Covered I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. INDUSTRY OVERVIEW 2. MARKET DYNAMICS 3. PRODUCT OVERVIEW 4. REGULATORY ENVIRONMENT & REIMBURSEMENTS 5. PRODUCT INNOVATIONS/INTRODUCTIONS - AlloSource Introduces AlloMend - Orthofix Launches Trinity? ELITE - Synergy Biomedical to Introduce Biosphere Putty - K2M Launches VENADO Bone Graft Systems - Bonesupport Receives CE Mark Approval for Cerament|G resorbable - PlusLife? Launches Innovative Allogeneic Bone Gel for Orthopedic Uses (Australia) - RTI Surgical Introduces BioReady DBM Putty - K2M Rolls Out VESUVIUS Osteobiologic Systems - BioHorizons Introduces MinerOss? Cancellous - Amedica Introduces Dynamic Bone - Orthogen Introduces NanoGen - SIRAKOSS Introduces MaxSi - BioMimetic to Introduce Augmatrix Biocomposite Bone Graft Line - Orthofix International Introduces Collage Osteoconductive Scaffold - BioMimetic Obtains Approval from TGA for Commercialization of Augment? Bone Graft - Medtronic Launches ARTISAN Space Maintenance System - NovaBone Introduces MacroPor-Si - RTI Surgical Announces First Application of map3TM Cellular Allogeneic Bone Graft in Ankle and Foot Fusion Procedures ( US) - Integra Receives FDA Clearance for Accell Evo3 - RTI Surgical Introduces BioAdapt DBM Foam - Integra Unveils Trel-Xpress Demineralized Bone Matrix - Keystone Dental Introduces DynaMatrix Plus - Wright Introduces FUSIONFLEX Demineralized Moldable Scaffold - Micromedics Launches OsteoXpress 15cc Bone Graft Delivery Device - Bacterin Unveils OsteoSponge?SC - Integra Launches Allograft Cancellous Sponge - Orthos Receives CE Approval for ?Gel Synthetic Bone Graft Substitute 6. RECENT INDUSTRY ACTIVITY - RTI Biologics Acquires Pioneer Surgical Technology - Wright Medical Group Acquires BioMimetic Therapeutics - Titan Spine Enters into Distribution Agreement with Biomet - Bioventus and Pfizer Enter into Agreement - AlloSource Enters into Partnership with Humacyte - MicroPort Medical to Acquire OrthoRecon Business of Wright Medical Group - J&J Takes Over Synthes - Stryker Acquires Orthovita - Zimmer Dental and Curasan Enter into Distribution Agreement - Cayenne Medical Enters into Partnership with Parametrics Medical - NuVasive Signs Licensing Agreement with AlloSource - Stryker Divests OP-1 Product Range 7. FOCUS ON SELECT PLAYERS 8. MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. EUROPE 3. REST OF WORLD IV. COMPETITIVE LANDSCAPE Companies Mentioned The report profiles 61 companies including many key and niche players such as: - AlloSource - Biomet - DePuy Synthes - Synthes - DePuy Spine - Exactech - Integra LifeSciences - LifeNet Health - Medtronic - NovaBone Products - NuVasive, - Olympus Biotech - RTI Surgical - Smith & Nephew - Stryker - Wright Medical Technology - BioMimetic Therapeutics - Zimmer For more information visit http://www.researchandmarkets.com/research/dt...one_grafts About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Why RTI Surgical, Inc. Shares Temporarily Spiked Higher
Sean Williams, The Motley Fool - Motley Fool - Wed Mar 12, 12:54PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of RTI Surgical , a producer of orthopedic...
Traders Get Bullish on Shares of RTI Biologics, Shares Up 7.1% (RTIX)
Comtex SmarTrend(R) - Wed Mar 12, 10:12AM CDT
RTI Biologics (NASDAQ:RTIX) is one of today's best performing low-priced stocks, up 7.1% to $4.23 on 1.6x average daily volume. Thus far today, RTI Biologics has traded 409,000 shares, vs. average volume of 262,000 shares per day. The stock has outperformed the Dow (7.1% to the Dow's -0.2%) and outperformed the S&P 500 (7.1% to the S&P's -0.2%) during today's trading.
RTI Surgical(TM) Launches Two Natural Bone Grafting Solutions at AAOS Annual Meeting
Business Wire - Wed Mar 12, 7:00AM CDT
RTI Surgical Inc. (RTI) (Nasdaq: RTIX), a leading global surgical implant company, is launching two new biological solutions at the American Academy of Orthopaedic Surgeons (AAOS) annual meeting in New Orleans this week. NanOss(R) Bioactive 3D, a synthetic three dimensional bioscaffold which supports bone formation, and map3(TM) Cellular Allogeneic Bone Graft, an implant that contains the three essential elements needed to generate and maintain new bone, will be introduced at the RTI Surgical exhibit at booth 5937 (Hall H) during the AAOS meeting.
Concise Analysis of the United States Regenerative Medicine Market - Forecasts to 2016
M2 - Wed Mar 12, 6:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4lq46f/regenerative) has announced the addition of the "Concise Analysis of the United States Regenerative Medicine Market - Forecasts to 2016" report to their offering. There is a high demand for synthetic organ transplants in the market. Regenerative medicine helps in the development of artificial organs. The introduction of artificial organs for implantation is expected to encourage many vendors and research organizations to develop advanced stem cell products, therapies, and regenerative products. It will also help reduce the long organ waiting list. For instance, custom-made windpipe can be made using regenerative products within a week. The first ever implant of a synthetic trachea took place in June 2011. The synthetic trachea was made from minuscule plastic fibers and was covered in stem cells taken from a human bone marrow. Surgeons successfully implanted this synthetic trachea into a 36-year-old patient with late-stage tracheal cancer at Karolinska University Hospital in Stockholm. Thus, the use of synthetic organs in transplant surgeries is expected to have a positive impact on the growth of the market. According to the report, one of the main drivers of this market is the increasing prevalence of degenerative diseases. Regenerative products have helped in addressing the unmet needs of various disease areas. Another major driver of the market is the significant advances seen in R&D. Key Topics Covered: 1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 5. Scope of the Report 6. Market Landscape 7. Vendor Landscape 8. Buying Criteria 9. Market Growth Drivers 10. Drivers and their Impact 11. Market Challenges 12. Impact of Drivers and Challenges 13. Market Trends 14. Key Vendor Analysis 15. Other Reports in this Series Companies Mentioned: - Advanced Cell Technology Inc. - Arteriocyte Inc. - Athersys Inc. - Baxter International Inc. - CryoLife - Cytori Therapeutics Inc. - Genzyme Corp. - Geron Corp. - InVivo Therapeutics - Inc. - Integra Life Sciences Holdings Corp. - Kensey Nash Corp. - Kinetic Concepts Inc. - Medtronic Inc. - NeoStem Inc. - Osiris Therapeutics Inc. - Osteotech Inc. - RTI Biologics Inc. - Stryker Corp. - Zimmer Holdings Inc. For more information visit http://www.researchandmarkets.com/research/4l...generative
